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Background: The transcription factor NFκB is an important mediator of cell survival and inflammation in the
immune system. In the central nervous system (CNS), NFκB signaling has been implicated in regulating neuronal
survival following acute pathologic damage such as traumatic brain injury (TBI) and stroke. NFκB is normally bound
by the principal inhibitory protein, IκBα, and sequestered in the cytoplasm. Activation of NFκB requires the
degradation of IκBα, thereby freeing NFκB to translocate to the nucleus and activate the target genes. Mice
deficient in IκBα display deregulated and sustained NFκB activation and early postnatal lethality, highlighting a
critical role of IκBα in NFκB regulation.
Results: We investigated the role of IκBα in regulating NFκB activity in the brain and the effects of the NFκB/IκBα
pathway in mediating neuroinflammation under both physiological and brain injury conditions. We report that
astrocytes, but not neurons, exhibit prominent NFκB activity, and that basal NFκB activity in astrocytes is elevated in
the absence of IκBα. By generating mice with brain-specific deletion of IκBα, we show that IκBα deficiency does not
compromise normal brain development. However, basal neuroinflammation detected by GFAP and Iba1
immunoreactivity is elevated. This leads to impaired inflammatory responses following TBI and worsened brain
damage including higher blood brain barrier permeability, increased injury volumes and enlarged ventricle volumes.
Conclusions: We conclude that, in the CNS, astrocyte is the primary cell type subject to NFκB regulation. We
further demonstrate that IκBα plays an important role in regulating NFκB activity in the brain and a robust NFκB/
IκBα-mediated neuroinflammatory response immediately following TBI is beneficial.
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Traumatic brain injury (TBI) is a major cause of mortal-
ity and disability in young adults and is particularly
prevalent among combat veterans of recent conflicts. Be-
sides the acute brain damage, TBI is associated with
increased risk of dementia later in life (reviewed in* Correspondence: huiz@bcm.edu
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reproduction in any medium, provided the or[1,2]). The pathophysiology of TBI is highly heteroge-
neous and complex. Following the primary mechanical
insults, TBI induces a multifactorial tissue response, in-
cluding the breakdown of blood–brain barrier (BBB) and
activation of inflammatory pathways, within hours to
days following the trauma, and these have been shown
to influence the neuronal survival and functional recov-
ery (reviewed in [3]). Neuroinflammation is a prominent
feature associated with TBI. In particular, TBI triggers
the activation of astrocytes and microglia and the release
of proinflammatory cytokines including TNFα, IL-1β
and IL-6 (reviewed in [4,5]). However, the functional. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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main controversial. In mouse and rat models of TBI,
some studies show that the cytokine release promotes
BBB breakdown and worsens brain damage and func-
tional outcome [6-10], while other reports suggest that
some aspects of inflammation may be beneficial to the
brain [4,11-14].
The transcription factor nuclear factor kappa B (NFκB)
is a master regulator of inflammation. It also mediates a
variety of other cellular processes including cell survival
and apoptosis (reviewed in [15]). NFκB activity is tightly
regulated. It is normally bound by the principal inhibi-
tory protein, IκBα, and is sequestered in the cytoplasm.
NFκB can be activated by cytokines or other stimuli in-
cluding trauma. This requires the degradation of IκBα
through the ubiquitin proteasome system, thereby free-
ing NFκB to translocate to the nucleus and activate the
target genes containing a consensus κB site in their pro-
moters [16,17], one of which is IκBα [18]. This forms an
effective feedback inhibitory loop, leading to the silen-
cing of NFκB. Accordingly, mice deficient in IκBα dis-
play deregulated and sustained NFκB activation and
early postnatal lethality [19,20], highlighting a critical
role of IκBα in NFκB regulation. NFκB activity is ele-
vated immediately following brain injury and sustained
for a long period of time afterwards [21-23]. Both neuro-
protective and neurotoxic roles of the NFκB pathway
have been proposed. One possible reason for these dual
effects of inflammation is that NFκB activation may in-
duce expression of different pathways in the brain. An-
other possibility is that the balance between the
beneficial and detrimental effects of inflammation may
be determined by the timing and intensity of the re-
sponse [15,24,25]. A better understanding of the com-
plex inflammatory response to brain injury may lead to
more effective treatment of TBI.
To bypass the lethality and to investigate the function
of the NFκB/IκBα pathway in adult brain, we generated
brain-specific IκBα conditional knockout mice. We show
that IκBα deficiency leads to elevated basal neuroinflam-
mation, resulting in a failure to mount proper inflamma-
tory responses following TBI and worsened brain
damage.
Results
Deletion of IκBα in the brain leads to upregulated
astroglia NFκB activity and neuroinflammation
We generated mice with specific deletion of IκBα in the
brain (IκBα cKO) by crossing an IκBα floxed allele [26]
with the Nestin-Cre [27] transgenic mice (Figure 1A).
Littermate IκBαfl/- mice without Cre transgene was used
as controls (Ctrl). Quantitative real-time PCR (qPCR)
analysis showed that the IκBα mRNA level was signifi-
cantly reduced (Figure 1B). Immunoblotting of IκBαrevealed a similar level of reduction in protein expres-
sion in the cKO mice (Figure 1C). In contrast to the
IκBα germline knockout mice, which are early postna-
tal lethal, the IκBα cKO mice are viable and overtly
normal. Nissl staining of adult IκBα cKO brains
revealed indistinguishable morphology compared to the
littermate controls (Figure 1D). Further quantification
of pyramidal neurons in CA1 region showed no overt
neurodegeneration in the IκBα cKO mice (Figure 1E)
and this is in agreement with their normal brain
weight (Figure 1F).
As a predominant inhibitor and downstream target of
NFκB, IκBα plays an essential role in regulating NFκB
activity. Both activation and suppression of NFκB by
IκBα have been reported, likely mediated in a cell type-
specific manner [19,20,26]. Accordingly, we prepared
primary neuronal and primary astrocyte cultures from
the germline IκBα knockout neonates and performed
immunostaining using an antibody that recognizes the
major NFκB subunit, p65 (Figure 2). Neurons from wild-
type (WT) and IκBα knockout (KO) mice showed simi-
lar weak and homogeneous p65 distribution over the
whole cell body (Figure 2A), indicative of non-specific
staining. This is corroborated by the similar staining pat-
tern following treatment with the potent NFκB activator
TNFα (Figure 2, B and quantified in F). Of interest, the
cells that show clear p65 nuclear translocation in re-
sponse to TNFα are NeuN-negative, likely due to the
contamination of glial cells in the culture (Figure 2B). In
contrast, strong cytoplasmic and weak nuclear staining
can be detected in GFAP-positive astrocytes using the
anti-p65 antibody (Figure 2C). The specificity of the sig-
nal was further confirmed by the robust nuclear trans-
location of p65 upon treating the cultures with TNFα
(Figure 2D). Measurement of nuclear and cytoplasmic
fluorescence intensity from the control and IκBα KO
astrocytes under basal condition revealed higher nuclear
to cytoplasmic ratio (Nuc/Cyt) in the absence of IκBα
(Figure 2G, WT vs. KO), suggesting that deleting IκBα
leads to higher basal NFκB activity. TNFα treatment led
to strong nuclear translocation of TNFα. However, p65
Nuc/Cyt ratio after TNFα treatment showed similar
values between WT and KO astrocytes likely caused by
oversaturated nuclear signal intensity (Figure 2G, WT+
TNFα vs. KO+TNFα). The enhanced basal nuclear
NFκB in KO astrocytes is further strengthened by quan-
tifying the nuclear NFκB levels in IκBα conditional
knockout mice in which IκBα is specifically deleted in
astrocytes by crossing the IκBα floxed allele with the
GFAP-Cre transgenic mice [28] (Figure 2H). Overall, our
results provide strong support for the notion that, in the
CNS, astrocyte is the primary cell type subject to NFκB
regulation and that loss of IκBα in astrocytes results in
higher basal NFκB activity. Nevertheless, we cannot
Figure 1 Generation and characterization of brain IκBα conditional knockout (cKO) mice. (A) Breeding scheme used for generating the
IκBα cKO mice and the littermate controls (Ctrl). (B) Real-time quantitative PCR (qPCR) analysis of IκBα mRNA (N= 3/genotype) and (C) Western
blot analysis of IκBα protein levels in brain lysates of 2–3 month old adult cKO and Ctrl hippocampal tissue. (D) Representative images of
Nissl-stained brain sections of 10–12 month old Ctrl and cKO mice. Scale bar: 1 mm. White boxes highlight the sampling region for counting
pyramidal neuronal number. (E) Quantification of pyramidal neurons in hippocampal CA1 region (N = 5/genotype) and (F) brain weight
measurements of Ctrl and IκBα cKO mice (N= 9-14/genotype).
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induced under pathological conditions in vivo.
Considering that NFκB is a master regulator of inflam-
matory responses, we tested the levels of neuroinflamma-
tion in IκBα cKO mice by immunostaining the brain
sections with antibodies against GFAP and Iba1 and quan-
tifying the number of astrocytes and microglia respectively
(Figure 3). Indeed, the number of GFAP- and Iba1-
positive cells in both the hippocampus (HPC) and cortex
(CTX) are significantly increased in IκBα cKO brains as
compared to their littermate controls (Figure 3B and D).
Attenuated neuroinflammatory response in IκBα deficient
brain following TBI
Neuroinflammation is an invariable feature associated
with TBI. This involves the activation of NFκB and the
release of pro-inflammatory cytokines including TNFα,
IL-1β and IL-6 by astrocytes and microglia. Having char-
acterized the IκBα cKO mice under basal condition, we
were interested in understanding how the basal activation
of NFκB affects the brain damage following TBI. We per-
formed controlled cortical impact (CCI), which is the
most-widely used protocol and known to induce moderate
to severe brain injury, to Ctrl and IκBα cKO mice, and
measured cytokine levels without injury (NT) or 3 hours
and 3 days after CCI (Figure 4A-C). As expected, levels of
IL6, IL-1β and TNFα protein displayed time-dependentkinetic changes. All cytokines were strongly upregulated
in response to the injury shortly after TBI (3 hour) but
returned close to baseline 3 days post injury (Figure 4A-C).
Noticeably, at 3 hour after injury, CCI-induced IL6 and IL-
1β overexpression was significantly lower in the absence of
IκBα (Figure 4A and B). This is also the case with TNFα al-
though to a lesser degree (Figure 4C). No group differences
were observed for cytokine expression either under basal
condition or 3 days post injury. Combined together, these
results indicate that the instant cytokine-associated inflam-
matory response to brain injury in IκBα cKO mice was
blunted while later-phase cytokine expression was largely
unaffected.
As expected, CCI resulted in prominent increase in re-
active astrocytosis and microgliosis in both the control
and IκBα cKO mice, quantified by GFAP- and Iba1-
immunoreactivity in both hippocampus and cortex
(Figure 4D-G). However and in contrast to the basal glia
activation in the IκBα cKO brains, the numbers of react-
ive astrocytes and microglia were overall similar between
the two groups with the IκBα cKO mice showing trends
of reduction. In fact, the level of astrocytosis was signifi-
cantly reduced in the hippocampus of the cKO mice
compared to the controls (Figure 4D). These lead to an
overall reduced degree of neuroinflammation in re-
sponse to TBI in the IκBα cKO mice, a notion that is in
agreement with their reduced cytokine release.
Figure 2 IκBα deletion results in increased NFκB activity in astrocytes. (A and B) Representative images of wild-type (WT) and IκBα
knockout (KO) primary neurons, either under basal condition (A) or treated with 50 ng/ml TNFα for 30 min (B), followed by staining against
neuronal marker Neuronal nuclei (NeuN) and NFκB subunit p65, and displayed as individual or merged images. Note the uniform p65 staining in
NeuN-positive neurons under both conditions and the cells that undergo p65 nuclear translocation in response to TNFα (B) are NeuN-negative.
(C and D) Representative images of primary astrocytes, either under basal condition (C) or treated with TNFα (D), followed by staining against
astroglia marker GFAP and p65, and displayed as individual or merged images. Note clear p65 nuclear translocation in GFAP-positive astrocytes.
(E) Representative p65 immunostaining of primary WT and KO astroglia cultures. (F) Quantification of relative p65 nuclear to cytoplasmic intensity
in WT and IκBα KO neurons with or without TNFα. (G) Quantification of relative p65 nuclear versus cytoplasmic fluorescence intensity in WT and
IκBα KO astrocytes in the presence or absence of TNFα stimulation, documenting increased basal p65 in IκBα KO sample and greatly enhanced
nuclear p65 upon TNFα treatment in both WT and KO cultures. N = 7-10/genotype. (H) p65 ELISA quantification of nuclear preparations from
adult (2–3 month) Ctrl and IκBα astroglia-specific knockout (GcKO) hippocampal samples. N = 3/genotype. ns: non-significant; *p < 0.05. Scale bar:
25 μm.
Lian et al. Molecular Neurodegeneration 2012, 7:47 Page 4 of 11
http://www.molecularneurodegeneration.com/content/7/1/47Loss of IκBα in the brain is associated with worsened
tissue damage following TBI
To test the functional effect of attenuated cytokine re-
lease resulting from brain IκBα deficiency, we performed
MRI scans to measure blood brain barrier (BBB) perme-
ability (Figure 5A) and tissue damage (Figure 5B) in con-
trol and IκBα cKO mice at 3 hours and 3 days post-TBI.
Quantification of MRI images showed that both the BBB
permeability (Figure 5D) and the volume of injured tis-
sue (Figure 5E) exhibited similar time-dependentdifferences as the cytokine profiles, i.e., significantly
higher BBB permeability and brain injury can be
detected in IκBα cKO mutant at 3 hours but not 3 days
after TBI. Altered cytokine expression and BBB perme-
ability in IκBα cKO mice immediately following TBI is
associated with their impaired long-term recovery. As-
sessment of morphological changes by Nissl staining of
comparable sections and quantification of the sizes of
left lateral ventricle (L-LV), dorsal third ventricle (D-LV)
and ventral third ventricle (V-3 V) 14 days after TBI
Figure 3 Elevated neuroinflammation in IκBα cKO mice. (A and C) Representative images of brain sections from 10–15 month-old mice Ctrl
and IκBα cKO mice stained against astroglia marker GFAP and microglia marker Iba1. HPC: hippocampus. CTX: cortex. (B and D) Quantification of
GFAP- and Iba1- positive cells in HPC and CTX respectively. N = 4/genotype. For each mouse, 3 evenly spaced sections were stained and
quantified. ***p < 0.001. Scale bar: 20 μm.
Figure 4 IκBα inactivation in the brain leads to blunted neuroinflammatory response following traumatic brain injury (TBI). TBI were
performed on 10–12 month old Ctrl and cKO mice. (A-C) IL6 (B), IL-1β (C) and TNFα (D) levels assayed by ELISA 3 hours and 3 days post-injury.
N = 3/genotype. (D-G) Relative GFAP-positive (D and E) or Iba1-positive (F and G) cells in HPC (D and F) or CTX (E and G) in response to TBI at
14 days after TBI. All values were normalized to numbers of NT Ctrl mice. N = 6 mice/genotype. For each mouse, 3 evenly spaced sections were
used for quantification. *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 5 IκBα cKO mice display increased BBB permeability and tissue damage after TBI. (A) Representative T1-weighted MRI images of
Ctrl and cKO mice 3 hour and 3 day after TBI. Water droplets (separate circles in upper left) serve as the background control and uninjured areas
(marked in yellow) are used as the internal control. Injured areas were marked in red. (B) Representative T2-weighted MRI images of Ctrl and cKO
mice 3 hour and 3 day after TBI with the injured brain tissue marked in red. (C) Representative images of Nissl stained brain sections from mice
survived 14 days after TBI. Scale bar: 1 mm. (D) Quantification of relative BBB permeability (normalized intensity) based on T1-weighted MRI
images shown in (A). N = 3 for each group. (E) Quantification of total injury volume based on T2-weighted MRI images shown in (B). N = 3 for
each group/time point. (F) Relative ventricular sizes were calculated as pixel numbers taken by ventricles divided by that of whole brain
substances based on Nissl staining results. L-LV: left lateral ventricle, D-3 V: dorsal third ventricle, V-3 V: ventral third ventricle. N = 5-6 mice/
genotype. *p < 0.05; **p < 0.01.
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tical difference, V-3 V was significantly enlarged in IκBα
cKO mice (Figure 5C and quantified in F).
Discussion
In the current study, we investigated the role of IκBα in
regulating brain NFκB activity and the output of the
NFκB/IκBα pathway in mediating neuroinflammation in
both basal and brain injury conditions. Using neuronal
and astrocytic cultures isolated from wild-type and IκBα
knockout mice, we show here that astrocytes, but not
neurons, exhibit prominent NFκB activity, and that
NFκB levels in astrocytes are elevated in the absence of
IκBα. IκBα deficiency in the brain does not compromise
normal brain development. However, basal neuroinflam-
mation detected by GFAP and Iba1 immunoreactivity is
increased. This leads to impaired inflammatory responses
following TBI and worsened brain damage including
higher blood brain barrier permeability and larger injury
volumes and enlarged ventricles in the brain.
NFκB has been shown to play important roles in nor-
mal brain development and neuronal survival and func-
tion [29-33]. This has been attributed, at least in part, by
the presence of constitutive NFκB activity in the neurons
and its further induction in response to multiple stimuli[34-38]. However, this notion was counted by a report
showing that neuronal NFkB was not responsive to a
variety of stimuli [39]. Importantly, a careful analysis
and comparison of an extensive list of NFκB antibodies
by Herkenham et al. documented that many of the anti-
bodies used to detect neuronal NFκB were not specific
to the target proteins and that the antibodies proven to
be specific to NFκB subunits failed to detect any consti-
tutive NFkB above background in neurons [40]. Our
results that neurons exhibit minimum levels of NFκB
and that it does not respond to TNFα treatment are
consistent with these recent studies. Therefore, it is pos-
sible that the neuronal phenotypes observed in various
NFκB mutant animals are originated from glia cells and
through neural-glia interactions. However, we cannot ex-
clude the possibility that neuronal NFkB may be induced
under pathological conditions in vivo.
In light of the critical role of IκBα in NFκB regulation,
the small (10-15%) increase in basal NFκB activity in
IκBα deficient samples is somewhat unexpected. Never-
theless, this subtle alteration is consistent with a previ-
ous report which measured NFκB activities in different
tissues and cell types of germline IκBα knockout mice,
the results of which revealed that the regulation of NFκB
by IκBα is cell type-dependent with brain displaying only
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[19]. The studies combined suggest that other IκB pro-
teins such as IκBβ may compensate for the loss of IκBα
in the brain, leading to overtly normal brain morphology
in CNS-specific IκBα conditional knockout mice. How-
ever, the dynamic roles played by IκBα in NFκB regula-
tion are unlikely to be fully replaced by other IκB
proteins. For instance, IκBβ or IκBE cannot efficiently
shuttle between nucleus and cytoplasm like IκBα does
[41] and their resynthesis rate after degradation are
much slower than IκBα [42]. This may explain the atte-
nuated instant inflammatory responses after TBI
observed in the IκBα cKO mice. Following this initial
period, nuclear NFκB activity gradually turns off and
other IκB proteins may eventually compensate for the
inhibitory function of IκBα [19,42]. Our results that after
3 days, cytokine levels and BBB permeability were simi-
lar between the control and IκBα cKO mice are consist-
ent with this assessment. Nevertheless, it remains
possible that the impaired response in the absence of
IκBα may be due to other unmeasured pathways in
addition to increased NFkB.
NFκB activity has been shown to be elevated immedi-
ately following brain injury and sustained for a long
period of time afterwards [21-23]. The activation of
NFκB triggers a pleiotropic response involving pathways
that both contribute to and protect from brain damage.
For example, on the one hand, NFκB activation results in
the release of proinflammatory cytokines, and potentially
neurotoxic reactive oxygen species and excitotoxins
[43,44]. On the other hand, it induces the expression of
anti-oxidants and pro-survival factors [45-47]. Activation
of NFκB in both residential astrocytes and microglia after
brain injury has been reported previously [21,48]. Add-
itionally, traumatic injury leads to compromised BBB
which may allow infiltration of peripheral lymphocytes
and secretion of cytokines into the brain [49]. Microglia
can trigger direct effect in response to TBI [50], it can
also undergo modulation by astrocytes [51,52]. The even-
tual worsened outcome after injury in the mutant mice
may be due to the insufficiency of astrocytic activation,
and/or ineffective microglial alteration directly or down-
stream of astrocyte activation. As immunocompetent
cells, astrocytes, compared to microglia or invading lym-
phocytes, displays extensive coverage of brain capillaries
[53] and intricate communication with other neural cells.
Astrocytes participate in BBB function and are capable to
affect BBB permeability [54,55]. The fact that worse BBB
permeability is associated with attenuated cytokine ex-
pression at 3 hr after CCI may be an evidence for the
beneficial role of robust inflammatory responses from
astrocytes in functional recovery after brain injury.
Deciphering the precise role of NFκB-mediated neu-
roinflammation will be beneficial for understanding thepotential of NFκB-based therapy. Our results suggest
that an initial robust neuroinflammatory response fol-
lowing TBI is beneficial for reducing brain damage.
Since the IκBα/NFκB pathway plays an important role in
mediating this response, transient activation of NFκB-
mediated neuroinflammation immediately after the brain
injury may be therapeutically beneficial.
Conclusions
Traumatic brain injury (TBI) affects a wide range of
individuals, from young adults to elderly and from civi-
lians to military combats, and cause both short-term
impairments and long-term consequences. The current
treatment is limited to symptom management and the
mechanisms leading to the short- and long-term effects
are poorly understood. A better understanding of the
molecular and cellular mechanisms of the various pro-
cesses accompanying TBI and their relation to functional
recovery is critical to identify effective therapies for TBI.
Our results demonstrate that a robust NFκB/IκBα-
mediated neuroinflammation immediately following TBI
is neuroprotective. Therefore, transient stimulation of
the neuroinflammatory response through NFκB activa-
tion may be therapeutically beneficial.
Methods
Animals
Mice were housed 2–5 per cage with ad libitum access
to food and water in a room with a 12 hr light/dark
cycle in a sterile pathogen-free mouse facility. All proce-
dures were performed in accordance with NIH guide-
lines and with the approval of the Baylor College of
Medicine Institutional Animal Care and Use Committee.
IκBα+/− mice [19] and Nestin-Cre transgenic mice [27]
are available from Jackson Laboratory. Astroglia-specific
IκBα knockout mice (IκBα GcKO) were generated using
the breeding as the same as that of IκBα cKO mice and
the GFAP-Cre transgenic mice used were obtained from
National Cancer Institute Mouse repository [28]. IκBα
floxed mice were obtained from Dr. Rudolf Rupec
(University of Munich, Germany) and have been described
previously [26]. All animals have been backcrossed onto
the C57BL/6 background for a minimum of six genera-
tions. Genotyping was performed by PCR of tail DNA at
time of weaning.
Controlled cortical impact (CCI)
Mice at 7–12 month old age were anaesthetized with
isoflurane and intubated to control ventilation. After
placement on a stereotaxic frame, a 3 mm craniotomy
was performed over the right parietal cortex. Injury was
induced using a voltage-driven impactor (3 m/sec,
1.5 mm deformation, 100 msec). The wounds were then
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recovery.
Magnetic resonance imaging (MRI)
Mice survived 3 hour or 3 day after TBI were MRI-
scanned to measure time-depended injury volume and
blood brain barrier permeability changes. Scans were
performed with a 9.4 T Bruker Avance Biospec Spec-
trometer, 21 cm bore horizontal scanner with a 35 mm
volume resonator (Bruker BioSpin) at 3 hrs post-TBI.
Mice were initially anesthetized with 5% isoflurane and
100% oxygen and then maintained on 1% to 2% isoflur-
ane during imaging. Respiration and temperature were
monitored using a respiratory pad and rectal probe, re-
spectively (Small Animal Instruments). The temperature
was maintained at 37°C with an air-heating system. First,
after the initial pilot scan, a high resolution, T2-
weighted, 3D RARE anatomical scan was performed to
allow for the segmentation and measurement of tissue
damage volumes. Then, we used dynamic MRI with con-
trast to assess the degree of BBB permeability. The mice
were placed into the magnet along with a water phan-
tom and T1-weighted, 2D multi-slice multi-spin scans
were obtained before and 5 min after Magnevist
(0.5 mM/kg) injection into the tail vein. Identical series
of T1-weighted scans were acquired (10 repetitions) to
observe the progression of contrast increase within the
tissue. The contralateral side of the brain to the injury
served as an internal control. After imaging, mice were
allowed to recover on a warmed heating pad prior to
being returned to their cage. Images were analyzed using
ImageJ software. To calculate size of injury, the area of
reactive brain was calculated in each 2D image slice,
multiplied by the interslice distance (0.5 mm), and then
summed. To calculate BBB permeability, an image slice
through the center of injury was selected and ROIs were
drawn in the water phantom, uninjured cortex, and
injured cortex for each repetition. The mean gray value
was then calculated for each ROI and the cortical values
were divided by the water value. The maximum normal-
ized intensity was then chosen.
Primary cell culture and immunocytochemistry
Cortices were isolated from new born pups (P0-P3) in
HBSS supplemented with 10 mM HEPES, 0.6% glucose,
1% v/v Pen/Strep under dissecting microscope and cut
into small pieces. Cortices was digested with 2.5% tryp-
sin and 1% DNAase I in HBSS at 37°C for 30 min and
trypsin inhibitor (1 mg/ml) was then added to stop di-
gestion. Tissue was collected after 1000 rpm for 10 min
and triturated and resuspended after centrifugation at
1000 rpm for another 10 min in culture media (For neu-
rons: Neurobasal medium supplemented with 2% B27,
0.5 mM L-glutamine, 0.4% v/v Pen/Strep; For astroglia,DMEM supplemented with 10% bovine calf serum and
1% v/v Pen/Strep). For neuronal culture, cells were pla-
ted onto poly-D-lysine (PDL)-coated glass coverslips at
50000 cells/cm2 and incubated at 37°C with 5% CO2 for
2 weeks before experiments. For astroglia, cells were pla-
ted in PDL-coated T-75 flasks at 50000 cells/cm2 and
when confluent, cultures were shaken at 220 rpm over-
night at 37°C to remove unwanted cell types (microglia,
neurons and fibroblasts). Pure astroglia cell cultures
were then trypsinized with 0.5% trypsin in EDTA and
plated onto PDL-coated glass coverslips. Glia cells were
used for immunocytochemical experiments after 7–10 days
incubation.
Cells were fixed in 4% PFA for 20 min, blocked with
3% goat serum in PBST for 1 hr and incubated in
primary antibodies (Rabbit anti-p65, cell signaling, 1:500,
Mouse anti-GFAP, Millipore, 1:1000; Mouse anti-
NeuN, Millipore, 1:1000) overnight at 4°C, followed by
incubation with secondary antibody (Goat anti-Rabbit-
Alexa555, Invitrogen, 1:2000; Goat anti-Mouse-
Alexa488, Invitrogen, 1:2000) diluted in blocking
solution for 2 hr at room temperature. Confocal im-
munofluorescent images of p65 in primary astroglia
were taken using a Leica DM2500B SPE confocal
microscope with a 20x objective. Images were ana-
lyzed by Adobe Photoshop. Nuclear area was defined
by DAPI and quantified for its mean grey value after
selection (VNuc). Cytoplasmic intensity was quantified
as the mean gray value of a cytoplasmic area with
exactly the same size as nuclear area close to the nu-
cleus (Vcyt). Nuclear/cytoplasmic fluorescent intensity
ratio was calculated as VNuc/Vcyt.
Quantitative real-time PCR (qRT-PCR)
Total RNA was isolated from snap frozen brain tissues
using the RNeasy Mini Lipid kit (Qiagen) and analyzed
as described previously [56]. RNA extracted from adult
2–3 month mice were tested for IkBa mRNA level re-
spectively. Samples from 2~ 4 mice for each genotype






Protein isolation, nuclear protein fractionation and
western blotting
Hippocampal or cortical tissues were homogenized in
RIPA buffer and centrifuged at 14000 rpm for 20 min.
Supernatant was collected and quantified using a DC
colorimetric protein assay (Bio-Rad). For nuclear protein
extraction, brain tissue was homogenized in extraction
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1 mM DTT, 0.5 mM PMSF supplemented with protease
and phosphatase inhibitors) and centrifuged at 1000xg
for 10 min at 4°C to pallet nuclear fraction. Pellet was
then rinsed with extraction buffer and resuspended in
buffer (20 mM HEPES, 400 mM NaCl, 1 mM EDTA,
1 mM EGTA, 1 mM DTT, 0.5% NP-40 supplemented
with protease and phosphatase inhibitors). Lysates were
boiled at 95°C for 7 min in sample buffer. 15 μg of pro-
tein samples were then loaded onto 12% SDS-
polyacrylamide gels, run at 100 V for 2 hr, transferred
onto nitrocellulose membranes (Bio-Rad) at 90 V for
1.5 hr at 4°C in transfer buffer (50 mM Tris, 40 mM gly-
cine, 20% methanol, 0.01% SDS), and blocked with 5%
milk in Tris-buffered saline containing 0.1% Tween-20
(TBST). The membranes were then probed with primary
antibodies (Rabbit anti-IκBα, Santa Cruz, 1:1000; Rabbit
anti-p65, Abcam, 1:1000; Mouse anti-γ-tubulin, Sigma,
1:20,000) diluted in blocking solution overnight at 4°C.
Membranes were washed 4 x 10 min in TBST and blot-
ted with secondary antibodies (Horse anti-Rabbit-HRP,
Vector Labs, 1:5000; Horse anti-Mouse-HRP, Vector
Labs, 1:5000) for 2 hr at room temperature. The mem-
branes were again washed 4 x 10 min in TBST, incu-
bated in ECL solution (GE Healthcare Life Sciences),
and exposed to film. After developing, the films were
digitized on a flatbed scanner.
Enzyme-linked immunosorbent assay (ELISA)
IL6, TNFα and IL-1β level in brain lysates collected from
mice at 3 hr and 3 day after TBI were determined using
mouse ELISA Ready-SET-Go kit (eBioscience). 100 μl of
concentration-determined protein samples were used for
detection according to the manufacturer’s instruction.
p65 levels in brain nuclear fraction from 2–3 month
adult mice were determined using Cayman NFκB ELISA
kit according to manufacturer’s instruction. The absorb-
ance was read on a spectrophotometer with a wave-
length of 450 nm. Absolute cytokine amount was
calculated based on the standard curve. Concentration
of ELISA-determined molecules was quantified as abso-
lute amount determined by the kit divided by total pro-
tein amount loaded and presented as pg/μg total
protein.
Histology and immunostaining
Mice were deeply anaesthetized, transcardiac perfused
with 4% PFA, and post-fixed in 4% PFA overnight at 4°C.
Brains were then transferred to water and then dehydrated
in progressively increasing concentrations of ethanol
before xylene incubation and paraffin embedding.
8 μm coronal sections were cut on a microtome,
dewaxed in xylene and then rehydrated in progressively
decreasing concentrations of ethanol. For Nissl staining,sections were incubated in cresyl violet solution and then
rinsed in water before dehydration and coverslip applica-
tion with a permanent mounting medium.
For immunostaining, antigen retrieval was performed
by boiling the sections in citrate buffer solution. Sections
were then permeabilized in PBS with 0.1% Triton X-100
(PBST) and blocked with 3% goat serum in PBST for
1 hr before incubation with primary antibodies (Rabbit
anti-GFAP, Sigma,1:1000; Rabbit anti-Iba1, Wako,1:1000)
diluted in blocking solution overnight at 4°C. Sections
were then washed in PBST 5 x 3 min before incubation
with secondary antibodies (Goat anti-Rabbit-Alexa555,
Invitrogen, 1:2000; Goat anti-Mouse-Alexa488, Invitro-
gen, 1:2000) diluted in blocking solution for 2 hr at
room temperature. Sections were again washed in PBST
5 x 3 min and placed on coverslips with Prolong Gold
AntiFade Reagent with DAPI (Invitrogen). Images were
taken using a Nikon epifluorescent microscope using
Metamorph software or with a high resolution slide
scanner.Quantification of pyramidal neuronal number in CA1
region and gliosis
3–4 equivalent brain sections were chosen from each
mouse for each type of quantification using dentate
gyrus as a reference. The total pyramidal neuronal num-
ber in the sampling regions with a length of 400 μm was
counted blindly using Nissl-stained sections. For quanti-
fication of gliosis, The total number of GFAP- or Iba1-
positive cells in dentate gyrus and the parallel cortical
regions were counted per high power field. Each group
was represented by 3–4 mice.Quantification of relative ventricular size
Five to 6 equivalent Nissl-stained brain sections per
genotype from mice survived 14 days after TBI were
selected based on the morphology of dentate gyrus in
the uninjured side for quantification of ventricular size
following CCI. Adobe Photoshop was used to quantify
pixel number of the ventricle area and whole brain sub-
stances. Relative ventricular sizes were calculated as ven-
tricular pixel number divided by pixels of brain
substances.Statistics
All data are presented as mean ± SEM. Outliers were
identified using Grubbs’ method with α= 0.05. Pairwise
comparisons were analyzed using a two-tailed Student’s
t-test, while a one-way or two-way ANOVA followed by
Bonferroni post-hoc analysis was used for multiple com-
parisons. P values less than or equal to 0.05 were consid-
ered statistically significant.
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